Hot Biotech Stocks For 2019

HC Wainwright set a $267.00 price target on Sarepta Therapeutics (NASDAQ:SRPT) in a research report report published on Tuesday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.

Several other research analysts have also issued reports on SRPT. Needham & Company LLC raised their target price on shares of Sarepta Therapeutics from $75.00 to $109.00 and gave the company a buy rating in a research note on Monday, May 7th. Barclays raised shares of Sarepta Therapeutics from an equal weight rating to an overweight rating and raised their target price for the company from $55.00 to $107.00 in a research note on Friday, May 11th. Leerink Swann raised their target price on shares of Sarepta Therapeutics from $88.00 to $121.00 and gave the company an outperform rating in a research note on Tuesday, May 15th. Goldman Sachs Group raised their target price on shares of Sarepta Therapeutics from $84.00 to $127.00 and gave the company a buy rating in a research note on Friday, May 18th. Finally, Zacks Investment Research lowered shares of Sarepta Therapeutics from a hold rating to a sell rating in a research note on Tuesday, May 22nd. Three analysts have rated the stock with a hold rating, twenty-two have issued a buy rating and one has given a strong buy rating to the company’s stock. Sarepta Therapeutics has an average rating of Buy and a consensus price target of $152.07.

Hot Biotech Stocks For 2019: Tortoise Energy Infrastructure Corporation(TYG)

Advisors’ Opinion:

  • [By Shane Hupp]

    UBS Group AG lifted its holdings in shares of Tortoise Energy Infrastructure Corp. (NYSE:TYG) by 5.5% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 205,851 shares of the financial services provider’s stock after buying an additional 10,728 shares during the period. UBS Group AG owned 0.42% of Tortoise Energy Infrastructure worth $5,142,000 at the end of the most recent reporting period.

Hot Biotech Stocks For 2019: Universal Health Services, Inc.(UHS)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Quorum Health (NYSE: QHC) and Universal Health Services (NYSE:UHS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, institutional ownership, profitability, earnings and risk.

  • [By Reuben Gregg Brewer]

     An aging baby boomer population is set to boost results at HCP, Inc. (NYSE:HCP) and Universal Health Services, Inc. (NYSE:UHS) for years to come. But is it better to own physical assets, like real estate investment trust HCP, or run them, like health facility operator Universal? In the end, these two companies are very similar but also differ in many ways. Here’s what you need to know to pick the one that’s right for you.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Universal Health Services, Inc. Class B (UHS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Max Byerly]

    Parametrica Management Ltd acquired a new stake in Universal Health Services (NYSE:UHS) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,694 shares of the health services provider’s stock, valued at approximately $201,000.

  • [By Shane Hupp]

    Nomura Asset Management Co. Ltd. boosted its stake in shares of Universal Health Services, Inc. Class B (NYSE:UHS) by 130.4% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 53,657 shares of the health services provider’s stock after buying an additional 30,365 shares during the quarter. Nomura Asset Management Co. Ltd. owned approximately 0.06% of Universal Health Services, Inc. Class B worth $6,353,000 as of its most recent SEC filing.

Hot Biotech Stocks For 2019: Greenlight Capital Re Ltd.(GLRE)

Advisors’ Opinion:

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Greenlight Capital Re (GLRE)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Max Byerly]

    Shares of Greenlight Capital Re, Ltd. (NASDAQ:GLRE) hit a new 52-week low on Wednesday . The company traded as low as $14.05 and last traded at $14.15, with a volume of 249308 shares changing hands. The stock had previously closed at $14.65.

  • [By Ethan Ryder]

    Greenlight Capital Re (NASDAQ:GLRE) last issued its quarterly earnings results on Monday, April 30th. The financial services provider reported ($3.85) EPS for the quarter, beating the consensus estimate of ($4.43) by $0.58. Greenlight Capital Re had a negative return on equity of 23.81% and a negative net margin of 40.65%. The firm had revenue of $0.14 million during the quarter, compared to analysts’ expectations of $30.20 million. sell-side analysts forecast that Greenlight Capital Re, Ltd. will post -4.2 earnings per share for the current fiscal year.

Leave a Reply

Your email address will not be published. Required fields are marked *